The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 22, 2008
Filed:
Dec. 17, 2001
Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
Jorge Berlanga Acosta, Habana, CU;
Gerardo Enrique Guillen Nieto, Habana, CU;
Diana Garcia Del Barco Herrera, Habana, CU;
Julio Raul Fernandez Masso, Habana, CU;
Mario Pablo Estrada Garcia, Habana, CU;
Isabel Guillen Perez, Habana, CU;
Jose Suarez Alba, Habana, CU;
Rebeca Martinez Rodriguez, Habana, CU;
Jorge Berlanga Acosta, Habana, CU;
Gerardo Enrique Guillen Nieto, Habana, CU;
Diana Garcia Del Barco Herrera, Habana, CU;
Julio Raul Fernandez Masso, Habana, CU;
Mario Pablo Estrada Garcia, Habana, CU;
Isabel Guillen Perez, Habana, CU;
Jose Suarez Alba, Habana, CU;
Rebeca Martinez Rodriguez, Habana, CU;
Centro de Ingenieria Genetica y Biotecnologia, Playa Ciudad de la Habana, CU;
Abstract
This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.